CODA Biotherapeutics just bought three failed drugs. Here’s why

CODA Biotherapeutics just bought three failed drugs. Here’s why

STAT Plus: This biotech just bought three failed drugs. Here’s why

By KATE SHERIDAN

ADOBE

CODA wants to use the drug candidates to activate the gene therapies it’s working on for a form of epilepsy and a neurological condition that causes pain. 

READ MORE